Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Low Ball Buyout!
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(112)
•••
Comment by MBT123on Dec 14, 2020 12:37am
186 Views
Post# 32097559

RE:RE:RE:Low Ball Buyout!

RE:RE:RE:Low Ball Buyout! Chrispi..Your a joke..Your going to use Home Depot as an example to a small bio tech with a part time CEO and a BOD that works even more part-time..The SP says all we need to know what anyone outside of here thinks about this 9yrs later! But keep buying the B.S. JD and DrR(part-time) are spewing it's done really well for us so far! Maybe get them a bigger mega-phone everything is fallen on deaf ears so far! But go ahead pull out some other comparisons or the deal and the company with no time lines etc..I'm all ears.Oh but we placed a guy with lots shares on the board for the "hypothetical" buyout that's going to really kick start this thing 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities